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Background: Effective testing is an essential tool for controlling COVID-19. We aimed to
analyse the data from first-wave PCR test results in Hungary’s Southern Transdanubian
region to improve testing strategies.
Methods: We performed a retrospective analysis of all suspected COVID-19 cases
between 17 March and 8 May 2020, collecting epidemiological, demographic, clinical
and outcome data (ICU admission and mortality) with RT-qPCR test results. Descriptive
and comparative statistical analyses were conducted.
Results: Eighty-six infections were confirmed among 3,657 tested patients. There
was no difference between the positive and negative cases in age and sex distribution;
however, ICU admission (8.1 vs. 3.1%, p= 0.006) and in-hospital mortality (4.7 vs. 1.6%,
p = 0.062) were more frequent among positive cases. Importantly, none of the initially
asymptomatic patients (n = 20) required ICU admission, and all survived. In almost
all cases, if the first test was negative, second and third tests were performed with a
48-h delay for careful monitoring of disease development. However, the positive hit rate
decreased dramatically with the second and third tests compared to the first (0.3 vs.
2.1%, OR = 0.155 [0.053–0.350]). Higher E-gene copy numbers were associated with
a longer period of PCR positivity.
Conclusion: In our immunologically naïve suspected COVID-19 population, coronavirus
infection increased the need for intensive care and mortality by 3–4 times. In the event
of the exponential phase of the pandemic involving a bottleneck in testing capacity, a
second or third test should be reconsidered to diagnose more coronavirus infections.
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INTRODUCTION
In December 2019, a new strain of human coronavirus, the Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),
emerged, causing the Coronavirus Disease 2019 (COVID-19) (1).
From the beginning of the pandemic to 1 November 2020, more
than 46 million individuals have been infected and more than 1.2
million have died from the infection in 216 affected countries (2).
Incidence is still rising on a global scale, and countries are well
into the second or third wave of the pandemic.
Due to the possibility of rapid human-to-human transmission
and lack of specific therapy, fast, and reliable diagnostic tests are
essential. Timely and rapid testing prevents the spread of the
virus and optimizes infection control measures. It enables early
case identification, isolation of cases and comprehensive contact
tracing (3). By the end of the first wave, it became clear that
countries that test more have lower mortality rates (4–6).
To identify active cases, nucleic acid amplification tests
(NAAT), such as the quantitative reverse-transcription
polymerase chain reaction (RT-qPCR) test, are the gold
standard (7, 8). During the pandemic, many countries have faced
difficulties in maintaining effective screening due to limited
access to laboratory equipment and commercial consumables for
PCR. Although these tests are now more widely available, rapid
increase in testing requirements in different loci throughout the
pandemic can interfere with testing capacity (9).
If transmission intensity exceeds testing capacity, countries
need to prioritize who will be tested. There are international
recommendations on the prioritization of testing among new
suspected cases. As regards retesting, protocols are not evidence-
based, and they differ among countries and hospitals (10).
Retesting of initially negative cases and follow-up testing of
positive cases need to be rationalized.
In addition to rationalizing the testing strategy, the allocation
of scarce resources among COVID-19 cases is vital. Timely
shifting of resources to higher risk groups is an option. Therefore,
identification of early prognostic factors can help clinicians’
decisions. Some risk factors, such as older age or obesity and the
presence of comorbidities, have already been identified (11, 12).
However, the role of several other factors is still unclear (13). For
instance, our understanding of differences between symptomatic
and asymptomatic cases is limited.
We aimed to analyse the data of first-wave PCR test results
in Hungary’s Southern Transdanubian region to aid in decision-
making on the necessity and timing of testing and retesting,
especially when testing capacity is limited.
MATERIALS AND METHODS
We performed a retrospective analysis of all suspected COVID-
19 cases between 17 March and 8 May 2020. We used the
definition of case according to the WHO interim guidance
(14). Diagnostic PCR tests were performed by the accredited
Department of Laboratory Medicine of the Medical School at the
University of Pécs. This center is responsible for PCR testing of
all samples in Hungary’s Southern Transdanubian region.
Patients Involved in the Analyses
Subjects enrolled in our epidemiological analysis were identified
for SARS-CoV-2 PCR testing by the regional offices of Hungary’s
National Public Health and Medical Officer Service, 29 health
care providers, including hospital and clinical sites, and
258 general practices in the Southern Transdanubian region
(including four counties: Somogy, Tolna, Baranya, and Zala).
All included cases were tested with PCR, and COVID-19 was
diagnosed based on WHO interim guidance.
Testing criteria covered epidemiological and/or clinical
indication (presence of symptoms listed on a questionnaire
provided by our laboratory). Health care personnel who were
contacts of confirmed COVID-19 patients were also enrolled.
Epidemiological indication for testing was defined as (1)
close contact with a confirmed COVID-19 case and (2) travel
from a COVID-19-affected area within 14 days to symptom
onset. Epidemiological risk assessment and contact tracing were
carried out by regional and national public health officers who
did interviews about exposure, travel history and symptoms,
identified contacts of confirmed COVID-19 patients, ordered
isolation and monitored symptom development.
Clinical indication for testing included (1) presence of
fever and/or upper and lower respiratory symptoms, (2)
cough, (3) chest discomfort or pain, (4) shortness of breath
or breathing difficulties, and (5) gastrointestinal symptoms,
including abdominal discomfort, nausea, vomiting, and
diarrhea. General practitioners and clinicians indicated testing
of symptomatic patients.
The algorithm for SARS-CoV-2 PCR testing is summarized in
Supplementary Figure 1.
Outcomes and Data Collections
Participants’ medical records were analyzed, and the following
epidemiological, demographic, clinical, and outcome data were
collected: reason for testing, date of sampling, age, gender,
presence of symptoms, viral excretion, ICU admission, and
mortality. Mortality data refer to the hospitalized period (in-
hospital mortality). An assessment of viral excretion is detailed
below and in Supplementary Document 1.
Sampling
Samples were taken by health care professionals at the National
Emergency Service or local health care providers. Specimens
were collected from the lower respiratory tract (with a tracheal
sputum) among hospitalized and ventilated cases and from the
upper respiratory tract (with a nasopharyngeal or oropharyngeal
swab) in all other participants. All specimens were labeled with
the patient (or contact) name, date of birth, specimen type, and
date, and time of collection.
Sample collection tubes were individually packaged in a sterile
double wall plastic bag and transferred to the laboratory at 4◦C
for nucleic acid extraction. Nucleic acid was extracted from
200 µl specimens either manually or with the MagNaPure 96
automated nucleic acid extraction system (Roche, Mannheim,
Germany). PCR amplification was carried out in LightCycler
480 and Cobas Z 480 PCR systems. Fluorescence data were
converted into concentrations using a standard curve and
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analyzed accordingly. The test was considered positive if the
sample was positive for at least two genes in the fortieth PCR cycle
(cycle threshold/Ct value= 40) (15). Sample processing and PCR
amplification are detailed in Supplementary Document 1.
Statistical Analyses
All of the statistical analyses were performed using the R
statistical environment, R Core Team v3.6.1 (16). A p-value
<0.05 was considered as statistically significant. For age, we
calculated the median and the range. The Wilcoxon Rank
Sum and Signed Rank Tests were used to compare the age
between the negative and positive cases. For sex, the presence of
symptoms, ICU admission and mortality odds ratios (OR) with
the corresponding 95% confidence interval (CI) were calculated
with the odds ratio function from the epitools package for R (17).
The Wilcoxon Rank Sum and Signed Rank Tests were used for
viral excretion (copy number of the E-gene).
Ethical Issues
In this study, data were collected retrospectively and analyzed
in compliance with ethical requirements. Ethical approval was
granted by the National Centre for Public Health (20800-
6/2020/EÜIG).
RESULTS
Between 17 March and 8 May 2020, 3,657 people with suspected
SARS-CoV-2 infection were tested in Hungary’s Southern
Transdanubian region, which represents 41.67 per thousand of
the resident population living there (18). Among individuals with
suspected COVID-19, a total of 5,463 tests were performed for
3,657 people, and 86 infections (2.35% of all participants and
1.57% of the total tests) were confirmed positive. The number of
tests performed showed a steady increase in the first week and
then relative stability until the end of the observation period. The
median age of the individuals tested was found to be 52 years
(range 0–98), and the proportion of male participants was 47.2%.
During the study period, the mean age and sex distribution also
showed relative constancy (Figure 1).
Dynamics of the COVID-19 Pandemic
The first case confirmed by PCR was found in Pécs on 18 March
2020, along with some symptomatic cases and contacts during
the following 5 days. The last new positive case was diagnosed
on 2 May. PCR-confirmed SARS-CoV-2-infected cases are
plotted on the map of Hungary’s Southern Transdanubian
region. The increase of incident cases representing the
dynamics of the pandemic spreading can be followed by 5-
day intervals (Figure 2). The mapping methodology is specified
in Supplementary Document 1. Most confirmed cases were
identified in large cities in the region, e.g., Pécs, while only a few
cases were found in rural areas there.
Clinical Characteristics of Coronavirus
Infection
Comparative analyses of the SARS-CoV-2 PCR test-positive
and test-negative subpopulations were performed for age, sex,
presence of symptoms, ICU admission and mortality (Figure 3).
There was no statistical difference between positive and negative
cases in terms of age at diagnosis (50.0 ± 17.9 vs. 51.3 ± 21.8,
respectively; W = 162,302, p = 0.353), but a slightly lower
proportion of women was observed among the confirmed cases
(46.5 vs. 53.4%, OR = 0.787 [0.510–1.209], p = 0.274). Among
suspected COVID-19 cases, the proportion of symptomatic
patients was higher in those with a positive test (76.7 vs. 60%,
OR = 2.146 [1.319–3.652], p = 0.001). ICU admission was
significantly more frequent in PCR positive cases compared to
negative ones (8.1 vs. 2.6%, OR= 3.379 [1.374–7.048], p= 0.010).
As regards ICU admitted cases, a higher proportion of male
participants was found in the confirmed group (85.7 vs. 57.0%,
OR = 0.248 [0.009–1.592], p = 0.158). Crude mortality among
the confirmed COVID-19 cases was marginally higher than of
the PCR negative group (4.7 vs. 1.6%, OR= 3.287 [0.957–8.291],
p= 0.057).
All patients had symptoms at the time of the first testing
among the PCR-positive participants, who later developed
severe outcomes and were admitted to the ICU (n = 7). As
regards deceased patients (n = 4), the proportion of initially
symptomatic cases was also 100%. We found that among initially
asymptomatic patients, no ICU admission or death occurred.
The mean age of participants admitted to the ICU was higher
compared to those who did not require intensive care. 85.7%
of ICU-admitted patients were male. The mean age of deceased
participants was higher compared to those who survived. Three
of the four deceased patients were male (Figure 3).
Testing Results of the General Population
and Health Care Providers
As the indication of RT-qPCR testing differs between the general
population and health care providers, we also analyzed these
two populations separately. During the observation period, we
identified 70 and 16 SARS-CoV-2-infected individuals in the
general population and among health care providers, respectively
(Figure 4; Supplementary Figure 2).
In the general population, the proportion of symptomatic
COVID-19 cases was 82.9%. Symptomatic COVID-19 cases had
higher viral excretion (copy number of the E-gene) compared
to those with asymptomatic infection, although the difference
was not statistically significant (328,694 ± 1,198,275 [n = 58] vs.
40,234 ± 110,046 [n = 12]; W = 257, p = 0.159). The rate of
cases that tested positive decreased with subsequent testing (2.1,
0.3, and 0.5% during the first, second, and third test, respectively).
92.9% of the positive participants tested positive on their first
PCR test. Only 7.1% of the RT-qPCR positive cases (n = 5) were
identified after a negative first test. Four infections (5.7%) were
confirmed with a second test, and only one (1.4%) was confirmed
with a third. The viral excretion of the infections identified later
was significantly lower compared to those with positive first tests
(230± 353 vs. 300,707± 1,134,581; W= 249, p= 0.0499).
Among health care providers, the proportion of symptomatic
COVID-19 cases was lower (50.0%). We did not find a difference
between symptomatic and asymptomatic health care providers
as regards viral excretion (8,901 ± 18,103 vs. 11,637 ± 22,711,
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FIGURE 1 | Age and sex distribution of the study population during the observation period.
FIGURE 2 | Incident cases representing the dynamics of the pandemic spreading in 5-day intervals. (A) Hungary and (B) south-western Hungary.
respectively; W = 10, p = 1). 56.3% of the participants
tested positive with the first RT-qPCR test among health care
professionals with confirmed infection. Contrary to the general
population, the viral excretion of infections identified later was
not different from those with positive first tests (10,117 ±
18,957 vs. 9,437 ± 23,326; W = 33, p = 0.916) among health
care providers.
Absolute quantification of the SARS-CoV-2 genetic
segments also allowed us to characterize the individual
disease progression with copy number changes. E-gene copy
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FIGURE 3 | Epidemiology and clinical outcome of the study population and comparison of negative and positive cases confirmed by polymerase chain reaction
(PCR). SYMP, symptoms; SD, standard deviation; ICU, intensive care unit; Mort, mortality.
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FIGURE 4 | Links between polymerase chain reaction (PCR) positivity with first and subsequent testing and viral excretion among the (A) general population and (B)
health care providers.
numbers intraindividually showed a decreasing tendency
parallel with the relief of clinical symptoms. Patients with
higher viral excretion tend to have a longer period of RT-qPCR
positivity (Supplementary Figure 3). Remission of the first
wave of the local outbreak was observed in close conjunction
with a decreasing frequency of the laboratory identification of
individuals with high E-gene copy number.
DISCUSSION
The coronavirus pandemic is spreading progressively. The
number of new cases diagnosed daily is still continuously
increasing worldwide. There are countries that have engaged in
an ongoing fight from the start, and there are countries over the
second wave of the pandemic. Even local interception of the fast
transmission has a significant impact on the economic and health
care burden. Analysis and interpretation of the early results of
different local outbreaks should not be delayed because analytical
learning is essential to developing effective prevention.
Importantly, if testing capacity becomes insufficient, countries
might need to prioritize who is tested (19). Under these
circumstances, the WHO recommends that tests be provided
for patients at higher risk for developing a more severe disease,
for first symptomatic patients in closed communities and for
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healthcare workers (14). However, we have no evidence on the
indication for retesting. Considering this question, our study
suggests other factors that would call for further research and
recommends their inclusion be considered in future guidelines.
In our study, the rate of cases tested positive decreased with
subsequent (second and third) testing; therefore, the number of
unnecessary repeat tests was high. This implies that if the number
of tests is limited, instead of retesting, resources should be
devoted to screening for other suspected COVID-19 cases where
the chances of test positivity are higher (20, 21). For example,
the presence of COVID-specific symptoms is an important factor
to consider (21). This is consistent with our results, as the
proportion of PCR-positive cases was higher among participants
with symptoms.
There is also no consensus on the timing of the follow-up
test. Local protocols mainly determine it by the time of symptom
onset and resolution (12). However, the duration of symptoms
and viral shedding is not always in synchrony; other factors
might therefore also be considered. In our study, higher initial
viral loads (E-gene copy numbers) were associated with longer
test positivity. This phenomenon has been described by Wolfel
et al. (22). They found that higher E-gene copy numbers were
associated with a more severe disease course, and the viral load
persisted longer compared to those who had lower copy numbers
(80 vs. 11 days). Therefore, retesting of patients with high viral
loads might be delayed, and the number of unnecessary tests
performed too early can be reduced among patients with a high
viral load.
In our study, cases with lower initial viral loads turned
negative earlier. The isolation and hospitalization could thus end
sooner for these patients, leading to economic benefits for both
individuals and societies. Lifting the quarantine sooner for these
patients can lead to decreased loss of daily wage earnings and
reduced isolation costs. In summary, in the case of a PCR test,
it is worth considering not only the fact of positivity, but also the
degree of viral load.
In addition to obvious infection control aspects, the
importance of identifying new cases is supported by the threefold
increase of ICU admission and mortality rates among the
COVID-19 positive cases in our study.
These results are likely to be independent of demographic
features, since they were similar among positive and negative
groups, except for the slightly higher rate of male participants
among the positive cases. A gender difference favoring men has
been observed in previous studies and suggests that the virus is
more likely to infect men (23, 24).
Among our limited number of positive cases, elderly, men and
symptomatic patients were more likely to be admitted to the ICU
or to die in our study, a finding which is consistent with previous
results (25).
Previous studies have implied that the vast majority of
asymptomatic patients at the time of the first positive test recover
spontaneously with a mild disease course (26, 27). We came
to the same conclusion since we found that no ICU admission
or death occurred among initially asymptomatic patients. These
patients thus do not require close observation, and the number of
follow-up examinations could therefore be minimized.
The literature suggests that asymptomatic patients can also
transmit the disease and viral excretion may be associated with
symptomatic patients (28, 29). In contrast, we found much lower
E-gene copy numbers in the asymptomatic cases emerging from
the general population compared to the symptomatic ones.
It is possible that some of these patients were pre-symptomatic
at the time of testing and developed symptoms later. A study
comparing truly asymptomatic and pre-symptomatic cases found
that the virus could be detected for a longer period in pre-
symptomatic cases (26, 30). If we add this to our findings of gene
copy number and duration of test positivity, truly asymptomatic
patients may be candidates for earlier retesting and released from
isolation as soon as possible.
Healthcare personnel were analyzed separately because the
PCR test indication was fundamentally different in their case,
and this population has different demographic characteristics.
In their case, our previous findings are not necessarily correct.
Nevertheless, it is difficult to draw a definite conclusion because
of the small sample size. We hypothesize that these individuals
may have been identified at an earlier stage of the disease. Based
on a previous study, we can also assume that they were exposed
to a lower viral load due to the use of protective equipment,
resulting in lower viral gene concentration in their samples (31).
Strength and Limitations
This is the first multi-center study in Hungary that reports on
the links between PCR testing and viral excretion, along with
demographic and clinical data. The observation period covers the
entire first wave of the region under pandemic surveillance of the
COVID-19 outbreak, and we included every sample of suspected
cases analyzed in the primary testing center Hungary’s Southern
Transdanubian region (32). Nevertheless, virus isolation was
mostly performed manually, which allows the detection of lower
virus copy numbers.
This study has some limitations. The first is the retrospective
nature of the data collection. Secondly, despite the large number
of tests performed, our conclusions may be limited by the
relatively low number of confirmed cases and its influence on
the power of the performed statistical analyses. Lastly, some
deviations occurred in distant areas following the strict screening
protocol in some cases, which resulted in missing data.
Although, most of our results are in line with exiting
published data, these new data from the specified Hungarian
population contribute to the knowledge and understanding of
this global pandemic.
Implication for Practice
• To avoid diagnostic insufficiency, when testing capacity
reaches its limits in the future, focusing on testing new cases
instead of repeated screening could be feasible.
• We recommend considering the viral copy number when
choosing the timing for retesting positive cases (follow-up
tests). Our results support earlier follow-up testing with lower
gene copy numbers and delayed follow-up testing with higher
copy numbers.
• Quantitative detection of viral excretion and different
segments of the viral genome which help to determine a
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potential infectious state may be useful for clinicians to plan
patientmanagement, placement in the proper health care ward
and translocation.
• We would like to draw clinicians’ attention to an important
finding: mortality and ICU admission were three times
more common among confirmed cases compared to “only”
suspected cases; however, further analyses are required with
larger datasets, as the difference was not significant due to the
low positive case numbers.
• Lack of symptoms at the time of the first test indicates a
good outcome.
Implications for Research
Additional studies are warranted to confirm our
recommendations. A particularly important area of research is
the relation between viral load and disease duration. Further
studies need to identify factors that can narrow the range of
testing indication in the case of insufficient testing capacity.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by National Center for Public Health (20800-
6/2020/EÜIG). Written informed consent from the participants’
legal guardian/next of kin was not required to participate in
this study in accordance with the national legislation and the
institutional requirements.
AUTHOR CONTRIBUTIONS
KG, PH, and AS: conceptualization. KG, LG, DC, KF, TN, and BS:
data collection and curation. KG, RH, and AS: formal analysis.
LG, DC, and PH: funding acquisition. KG, AG, TN, AM, PH,
and AS: methodology. AG, AM, and PH: resources. AG, PH, and
AS: supervision. RH and AS: visualization. KG, MF, SK, and PH:
writing – original draft. KG, MF, SK, RH, AG, LG, DC, KF, TN,
AM, BS, PH, and AS: writing – review & editing. All authors
contributed to the article and approved the submitted version.
FUNDING
This study was funded by the Economic Development and
Innovation Operational Programme within the framework of
the Széchenyi 2020 Programme (GINOP-2.3.2-15-2016-00048 –
Stay Alive to PH and GINOP-2.3.4-15-2020-00010 Competence
Center for Health Data Analysis, Data Utilization and Smart
Device and Technology Development at the University of Pécs),
the Human Resources Development Operational Programme
(EFOP 3.6.2-16-2017-00006 – Live Longer to PH), and the EU
Social Fund (EFOP-3.6.2-16-2017-00008, The role of neuro-
inflammation in neurodegeneration: from molecules to clinics to
LG and DC).
ACKNOWLEDGMENTS
The analysis was conducted on behalf of the Translational Action
and Research Group against Coronavirus (KETLAK) Study
Group. The authors wish to thank Dr. Gabriella Kiss and Dr. Eva
Suszter, epidemiology experts at the National Public Health and
Medical Officer’s Service, for their continuous consultation and
support throughout the outbreak.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fmed.
2020.625673/full#supplementary-material
Supplementary Figure 1 | The algorithm for SARS-CoV-2 polymerase chain
reaction (PCR) testing.
Supplementary Figure 2 | Polymerase chain reaction (PCR) results, viral
excretion and presence of symptoms with first test among the (A) general
population and (B) health care providers. SP, symptomatic positive; NSP,
non-symptomatic positive; SN, symptomatic negative; NSN,
non-symptomatic negative.
Supplementary Figure 3 | Results of individual disease progression with E-gene
copy number changes.
Supplementary Document 1 | Details of the assessment of viral excretion,
sample processing, PCR amplification, and mapping methodology.
Supplementary Table 1 | (A) Median, quartiles, minimum and maximum values
in the negative and positive severity and mortality groups. (B) Sex distribution,
symptoms, severity and mortality among positive cases in the normal population
and healthcare personnel groups. (C) Sex distribution, symptoms, severity and
mortality in the negative and positive groups. (D) First, second and third test
positivity in the normal population.
REFERENCES
1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology
in Wuhan, China: the mystery and the miracle. J Med Virol. (2020) 92:401–2.
doi: 10.1002/jmv.25678
2. Johns-Hopkins-Coronavirus-Resource-Center (2020). Available online at:
https://coronavirus.jhu.edu/map.html (accessed November 1, 2020).
3. Wu Z, McGoogan JM. Characteristics of and important lessons
from the coronavirus disease 2019 (COVID-19) outbreak in China:
summary of a report of 72314 cases from the Chinese center for disease
control and prevention. JAMA. (2020) 323:1239–42. doi: 10.1001/jama.
2020.2648
4. Di Bari M, Balzi D, Carreras G, Onder G. Extensive testing may reduce
COVID-19 mortality: a lesson from northern Italy. Front Med. (2020) 7:402.
doi: 10.3389/fmed.2020.00402
5. Hisaka A, Yoshioka H, Hatakeyama H, Sato H, Onouchi Y, Anzai N. Global
comparison of changes in the number of test-positive cases and deaths by
coronavirus infection (COVID-19) in the world. J Clin Med. (2020) 9:1904.
doi: 10.3390/jcm9061904
6. Kenyon C. Intensive COVID-19 testing associated with reduced mortality
- an ecological 2 analysis of 108 countries. Health Aff. (2021) 40:1.
doi: 10.1101/2020.05.28.20115691
7. Bustin SA, Nolan T. RT-qPCR testing of SARS-CoV-2: a primer. Int J Mol Sci.
(2020) 21:3004. doi: 10.3390/ijms21083004
Frontiers in Medicine | www.frontiersin.org 8 January 2021 | Volume 7 | Article 625673
Gombos et al. Analysis of COVID-19 Test Results in Hungary
8. Waller JV, Kaur P, Tucker A, Lin KK, Diaz MJ, Henry TS, et al.
Diagnostic tools for coronavirus disease (COVID-19): comparing CT and
RT-PCR viral nucleic acid testing. AJR Am J Roentgenol. (2020) 215:834–8.
doi: 10.2214/AJR.20.23418
9. Cheemarla NR, Brito AF, Fauver JR, Alpert T, Vogels CBF, Omer
SB, et al. Host response-based screening to identify undiagnosed cases
of COVID-19 and expand testing capacity. medRxiv [Preprint]. (2020).
doi: 10.1101/2020.06.04.20109306
10. European-Centre-for-Disease-Prevention-and-Control. Guidance for
discharge and ending isolation in the context of widespread community
transmission of COVID-19 [Online]. (2020). Available online at: https://www.
ecdc.europa.eu/en/publications-data/covid-19-guidance-discharge-and-
ending-isolation (accessed November 1, 2020).
11. Földi M, Farkas N, Kiss S, Zadori N, Vancsa S, Szako L, et al. Obesity is a risk
factor for developing critical condition in COVID-19 patients: a systematic
review andmeta-analysis.Obes. Rev. (2020) 21:e13095. doi: 10.1111/obr.13095
12. Zádori N, Vancsa S, Farkas N, Hegyi P, Eross B, Group KS. The negative
impact of comorbidities on the disease course of COVID-19. Intensive Care
Med. (2020) 46:1784–6. doi: 10.1007/s00134-020-06161-9
13. Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit
E, et al. Prediction models for diagnosis and prognosis of covid-19
infection: systematic review and critical appraisal. BMJ. (2020) 369:m1328.
doi: 10.1136/bmj.m1328
14. World-Health-Organization. Laboratory testing strategy recommendations




15. TIB_Molbiol_Berlin. Instructions for use LightMix Modular SARS andWuhan
CoV E-gene [Online]. (2020). Available online at: https://www.tib-molbiol.de/
de/ (accessed December 17, 2020).
16. R-Core-Team. R: A language and environment for statistical computing
[Online]. (2019). Vienna: R Foundation for Statistical Computing. Available
online at: https://www.r-project.org/ (accessed December 17, 2020).
17. Aragon TJ. epitools: Epidemiology Tools. R package version 0.5-10.1 [Online].
(2020). Available online at: https://cran.r-project.org/web/packages/epitools/
index.html (accessed December 17, 2020).
18. Hungarian-Central-Statistical-Office. Gazetteer of Hungary, 1 January 2019
[Online]. (2019). Available online at: https://www.ksh.hu/docs/hun/hnk/hnk_
2019.pdf (accessed November 1, 2020).
19. Gombos K, Herczeg R, Eross B, Kovacs SZ, Uzzoli A, Nagy T, et al. Translating
scientific knowledge to government decisionmakers has crucial importance in
the management of the COVID-19 pandemic. Popul. Health Manag. (2020).
doi: 10.1089/pop.2020.0159. [Epub ahead of print].
20. Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman
M, et al. Diagnostic testing for severe acute respiratory syndrome-related
coronavirus 2: a narrative review. Ann Intern Med. (2020) 172:726–34.
doi: 10.7326/M20-1301
21. Sharfstein JM, Becker SJ, Mello MM. Diagnostic testing for the
novel coronavirus. JAMA. (2020) 323:1437–8. doi: 10.1001/jama.
2020.3864
22. Wolfel R, Corman VM, GuggemosW, SeilmaierM, Zange S, Muller MA, et al.
Virological assessment of hospitalized patients with COVID-2019. Nature.
(2020) 581:465–9. doi: 10.1038/s41586-020-2196-x
23. Baggett TP, Keyes H, Sporn N, Gaeta JM. Prevalence of SARS-CoV-2 infection
in residents of a large homeless shelter in Boston. JAMA. (2020) 323:2191–2.
doi: 10.1001/jama.2020.6887
24. Xie S, Zhang G, Yu H, Wang J, Wang S, Tang G, et al. The epidemiologic
and clinical features of suspected and confirmed cases of imported 2019 novel
coronavirus pneumonia in north Shanghai, China. Ann Transl Med. (2020)
8:637. doi: 10.21037/atm-20-2119
25. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A,
et al. Baseline characteristics and outcomes of 1591 patients infected with
SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. (2020)
323:1574–81. doi: 10.1001/jama.2020.5394
26. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics
of 24 asymptomatic infections with COVID-19 screened among close
contacts in Nanjing, China. Sci China Life Sci. (2020) 63:706–11.
doi: 10.1007/s11427-020-1661-4
27. Wu Z, McGoogan JM. Asymptomatic and pre-symptomatic COVID-19 in
China. Infect Dis Poverty. (2020) 9:72. doi: 10.1186/s40249-020-00679-2
28. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed
asymptomatic carrier transmission of COVID-19. JAMA. (2020) 323:1406–7.
doi: 10.1001/jama.2020.2565
29. Huff HV, Singh A. Asymptomatic transmission during the COVID-19
pandemic and implications for public health strategies. Clin Infect Dis. (2020)
28:ciaa654. doi: 10.1093/cid/ciaa654
30. Walsh KA, Jordan K, Clyne B, Rohde D, Drummond L, Byrne P, et al. SARS-
CoV-2 detection, viral load and infectivity over the course of an infection. J
Infect. (2020) 81:357–71. doi: 10.1016/j.jinf.2020.06.067
31. Clementi N, Ferrarese R, Tonelli M, Amato V, Racca S, Locatelli M, et al.
Lower nasopharyngeal viral load during the latest phase of COVID-19
pandemic in a Northern Italy University Hospital. Clin Chem LabMed. (2020)
58:1573–7. doi: 10.1515/cclm-2020-0815
32. World-Health-Organization. Laboratory testing for 2019 novel coronavirus
(2019-nCoV) in suspected human cases [Online]. (2019). Available online at:
https://www.who.int/publications/i/item/laboratory-testing-for-2019-novel-
coronavirus-in-suspected-human-cases-20200117 (accessed November 1,
2020).
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Gombos, Földi, Kiss, Herczeg, Gyenesei, Geiger, Csabai, Futács,
Nagy, Miseta, Somogyi, Hegyi and Szentesi. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Medicine | www.frontiersin.org 9 January 2021 | Volume 7 | Article 625673
